952
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Increased risk of subclinical atherosclerosis associated with high visceral adiposity index in apparently healthy Korean adults: the Kangbuk Samsung Health Study

, , , , , , & show all
Pages 410-416 | Received 01 Mar 2016, Accepted 22 Apr 2016, Published online: 14 May 2016

References

  • Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American diabetes association and the American heart association. Circulation. 2006;113:2943–6.
  • Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093–100.
  • Ferrannini E. Is insulin resistance the cause of the metabolic syndrome? Ann Med. 2006;38:42–51.
  • Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–19.
  • Oh JY. Regional adiposity, adipokines, and insulin resistance in type 2 diabetes. Diabetes Metab J. 2012;36:412–14.
  • Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med. 2006;38:52–63.
  • Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14:1132–43.
  • Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care. 2005;28:2322–5.
  • Pascot A, Lemieux S, Lemieux I, Prud'homme D, Tremblay A, Bouchard C, et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care. 1999;22:1471–8.
  • Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881–7.
  • Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am. 2003;23:15–39.
  • DeNino WF, Tchernof A, Dionne IJ, Toth MJ, Ades PA, Sites CK, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001;24:925–32.
  • Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the determination of body fat by computed tomography. Int J Obes. 1983;7:437–45.
  • Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metab Clin Exp.1987;36:54–9.
  • Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose-tissue distribution-a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr. 1990;51:953–7.
  • Ryo M, Kishida K, Nakamura T, Yoshizumi T, Funahashi T, Shimomura I. Clinical significance of visceral adiposity assessed by computed tomography: a Japanese perspective. World J Radiol. 2014;6:409–16.
  • Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J. 2002;66:987–92.
  • Despres JP, Lamarche B. Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease. Nutr Res Rev. 1993;6:137–59.
  • Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12:295–300.
  • Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–2.
  • Ding Y, Gu D, Zhang Y, Han W, Liu H, Qu Q. Significantly increased visceral adiposity index in prehypertension. PLoS One. 2015;10:e0123414.
  • Oh JY, Sung YA, Lee HJ. The visceral adiposity index as a predictor of insulin resistance in young women with polycystic ovary syndrome. Obesity (Silver Spring, Md). 2013;21:1690–4.
  • Han L, Fu KL, Zhao J, Wang ZH, Tang MX, Wang J, et al. Visceral adiposity index score indicated the severity of coronary heart disease in Chinese adults. Diabetol Metab Syndr. 2014;6:143
  • Salazar MR, Carbajal HA, Espeche WG, Aizpurúa M, Maciel PM, Reaven GM. Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio. Am J Med. 2014;127:152–7.
  • Alluri K, Joshi PH, Henry TS, Blumenthal RS, Nasir K, Blaha MJ. Scoring of coronary artery calcium scans: history, assumptions, current limitations, and future directions. Atherosclerosis. 2015;239:109–17.
  • Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–45.
  • American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016;39 Suppl 1:S13–22.
  • Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–52.
  • Ishiyama M, Suzuki E, Katsuda J, Murase H, Tajima Y, Horikawa Y, et al. Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients. Diabetes Res Clin Pract. 2009;85:189–96.
  • Mikami S, Hamano T, Fujii N, Nagasawa Y, Isaka Y, Moriyama T, et al. Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients. Hypertens Res. 2008;31:1163–70.
  • Han D, Ó Hartaigh B, Gransar H, Yoon JH, Kim KJ, Kim MK, et al. Incremental benefit of coronary artery calcium score above traditional risk factors for all-cause mortality in asymptomatic Korean adults. Circ J. 2015;79:2445–51.
  • Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010;21:345–52.
  • Du T, Zhang J, Yuan G, Zhang M, Zhou X, Liu Z, et al. Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes. Nutr Metab Cardiovasc Dis. 2015;25:100–7.
  • Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, et al. Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38:81–9.
  • Chen HY, Chiu YL, Chuang YF, Hsu SP, Pai MF, Yang JY, et al. Visceral adiposity index and risks of cardiovascular events and mortality in prevalent hemodialysis patients. Cardiovasc Diabetol. 2014;13:136.
  • Bays HE. “Sick fat,” metabolic disease, and atherosclerosis. Am J Med. 2009;122:S26–S37.
  • Lim S. Ectopic fat assessment focusing on cardiometabolic and renal risk. Endocrinol Metab (Seoul). 2014;29:1–4.
  • Naboush A, Hamdy O. Measuring visceral and hepatic fat in clinical practice and clinical research. Endocr Pract. 2013;19:587–9.
  • Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.